Enovis (NYSE:ENOV) CEO Damien Mcdonald Purchases 13,035 Shares of Stock

Enovis Corporation (NYSE:ENOV) CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The stock was bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Enovis Trading Down 4.2%

NYSE:ENOV opened at $18.58 on Friday. Enovis Corporation has a 12-month low of $18.52 and a 12-month high of $34.28. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock’s 50 day simple moving average is $25.50 and its 200-day simple moving average is $24.20. The firm has a market cap of $1.07 billion, a P/E ratio of -0.96 and a beta of 1.31.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period last year, the company earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts anticipate that Enovis Corporation will post 3.15 EPS for the current year.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ENOV shares. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. BMO Capital Markets set a $27.00 price target on Enovis in a research note on Tuesday. Citizens Jmp dropped their price objective on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday. Canaccord Genuity Group reduced their price objective on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Finally, Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.38.

Institutional Trading of Enovis

Institutional investors and hedge funds have recently modified their holdings of the business. Arax Advisory Partners purchased a new position in shares of Enovis during the 4th quarter worth approximately $29,000. Allworth Financial LP purchased a new stake in Enovis in the 2nd quarter valued at approximately $36,000. EverSource Wealth Advisors LLC lifted its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Enovis during the 2nd quarter valued at $48,000. Finally, Danske Bank A S acquired a new stake in Enovis during the 3rd quarter valued at $64,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.